Cargando…
Recombinant Human Epo Treatment: Beneficial in Chronic Kidney Disease, Chronic Heart Failure, or Both?: Editorial to: “Correction of Anemia with Erythropoietin in Chronic Kidney Disease (Stage 3 or 4): Effects on Cardiac Performance by Pappas et al.”
Autores principales: | Belonje, A. M. S., de Boer, R. A., Voors, A. A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer US
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2243255/ https://www.ncbi.nlm.nih.gov/pubmed/18219567 http://dx.doi.org/10.1007/s10557-008-6079-x |
Ejemplares similares
-
The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia
por: Landau, Daniel, et al.
Publicado: (2018) -
Comparative Study of Recombinant Human Erythropoietin (rhEPO)
Products on CKD (Chronic Kidney Disease) Patients
por: Dwitanto, Kuspuji, et al.
Publicado: (2023) -
Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin
por: Hanna, Ramy M., et al.
Publicado: (2020) -
Erythropoietin (EPO) in acute kidney injury
por: Moore, Elizabeth, et al.
Publicado: (2011) -
Erythropoietin stimulating agents in the management of anemia of chronic kidney disease
por: Hayat, Amir, et al.
Publicado: (2008)